Recursion Pharmaceuticals, Inc. (RXRX) Insider Trading

Over the last 3 months, RXRX insiders made 0 open-market buys and 11 sales, a net sale of -$1.1M (SEC Form 4). Over the last 6 months, 288 institutions increased and 171 reduced their position (13F).

Insider Activity

Sentiment
0/100
Buys (3m)
0
Sells (3m)
11
Net (3m)
-$1.1M
Insider trades by month Buys Sells
Jan
Feb
Mar
Apr
May
Jun
Context3-month price -4.7%Institutions accumulating (13F)
DateInsiderTypeSharesPrice
Jun 4, 2026Bumpus NamandjedirectorSell4,386$3.54
Jun 4, 2026Borgeson BlakedirectorSell30,000$3.68
May 27, 2026Gibson ChristopherdirectorSell40,000$3.08
May 19, 2026Gibson ChristopherdirectorTax22,821$3.04
May 19, 2026Khan Najatdirector, officer: CEO and PresidentTax62,701$3.04
May 19, 2026Taylor Ben Rofficer: Chief Financial OfficerTax25,018$3.04
May 19, 2026Hallett Davidofficer: Chief Scientific OfficerTax26,657$3.04
May 8, 2026Gibson ChristopherdirectorSell40,000$3.37
May 7, 2026Borgeson BlakedirectorSell30,000$3.52
Apr 24, 2026Gibson ChristopherdirectorSell40,000$3.61
Apr 8, 2026Taylor Ben Rofficer: Chief Financial OfficerTax48,028$3.11
Apr 8, 2026Borgeson BlakedirectorSell30,000$3.10
Apr 8, 2026Gibson ChristopherdirectorSell40,000$3.10
Apr 2, 2026Dar ZavaindirectorGrant4,902
Apr 2, 2026Li Dean YdirectorGrant3,268
Mar 25, 2026Gibson ChristopherdirectorSell40,000$3.25
Mar 18, 2026Taylor Ben Rofficer: Chief Financial OfficerSell7,956$3.39
Mar 18, 2026Taylor Ben Rofficer: Chief Financial OfficerTax7,075$3.42
Mar 11, 2026Khan Najatdirector, officer: CEO and PresidentSell28,298$3.35
Mar 4, 2026Borgeson BlakedirectorSell170,000$3.46
Feb 19, 2026Taylor Ben Rofficer: Chief Financial OfficerSell13,426$3.08
Feb 19, 2026Hallett Davidofficer: Chief Scientific OfficerTax11,908$3.49
Feb 19, 2026Gibson ChristopherdirectorTax27,265$3.49
Feb 19, 2026Taylor Ben Rofficer: Chief Financial OfficerTax11,908$3.49
Feb 19, 2026Khan Najatdirector, officer: CEO and PresidentTax14,280$3.49
Feb 19, 2026Gibson ChristopherdirectorSell40,000$3.46
Feb 10, 2026Taylor Ben Rofficer: Chief Financial OfficerGrant24,254
Feb 10, 2026Hallett Davidofficer: Chief Scientific OfficerGrant502,064
Feb 10, 2026Khan Najatdirector, officer: CEO and PresidentGrant1,673,546
Feb 10, 2026Hallett Davidofficer: Chief Scientific OfficerTax11,400$3.98

Source: RXRX SEC Form 4 filings, latest Jun 4, 2026. For informational purposes only — not investment advice.

Institutional activity (13F)

How institutions changed their RXRX positions over the last 6 months (SEC Form 13F).

Increased
288
New positions
110
Reduced
171
Sold out
100
Largest moves
InstitutionActionSharesFiled
VANGUARD GROUP INCIncreased47.2MJan 29, 2026
BLACKROCK, INC.Increased43.2MMay 13, 2026
ARK INVESTMENT MANAGEMENT LLCIncreased40.2MMay 12, 2026
BLACKROCK, INC.Increased38.9MFeb 12, 2026
ARK INVESTMENT MANAGEMENT LLCIncreased37.3MFeb 11, 2026
STATE STREET CORPIncreased28.5MMay 15, 2026
STATE STREET CORPIncreased25.3MFeb 13, 2026
BAILLIE GIFFORD & COReduced23.8MJan 23, 2026
BAILLIE GIFFORD & COReduced23.7MMay 8, 2026
VANGUARD PORTFOLIO MANAGEMENT LLCNew Position22.8MMay 8, 2026
VANGUARD CAPITAL MANAGEMENT LLCNew Position22.2MMay 15, 2026
SOFTBANK GROUP CORP.Reduced13.6MFeb 17, 2026
SOFTBANK GROUP CORP.Unchanged13.6MMay 15, 2026
GEODE CAPITAL MANAGEMENT, LLCIncreased12.3MMay 15, 2026
GEODE CAPITAL MANAGEMENT, LLCIncreased10.9MFeb 9, 2026

Source: SEC Form 13F filings. For informational purposes only — not investment advice.